

Drug and Therapeutics Committee – Minutes

Date / Time	August 11 th 2022
Venue	WebEx
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
Quorate: Yes / No	Yes

Attendance	Prof A Morice, Chair, Professor of Respiratory Medicine Prof M Lind, Vice Chair, Professor of Oncology, HUTH Mr K McCorry, Medicines Optimisation Pharmacist, NECS Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH Dr O Ogunbambi, Consultant Rheumatologist, HUTH Ms J Goode, Chief Pharmacist, HUTH Dr S Raise, GP Prescribing Lead, ER CCG Dr H Klonin, Consultant Paediatrician, HUTH Mr P O'Brien, Deputy Chief Pharmacist, HUTH Prof T Sathyapalan, Consultant Endocrinologist, HUTH
-------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Apologies

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.08.01	Apologies	As Above.					
2022.08.02	Declarations of Interest	None					
2022.08.03	Minutes of the previous meeting	Accepted as an accurate record	no action required				
2022.08.04	Action Tracker	<p>Hydroxychloroquine in RA JM to discuss with relevant business managers- JM tried to contact ophthalmology business manager with no success. AM suggest that it should be escalated if unable to discuss with ophthalmology business manager.</p> <p>ARIA forms – Zoledronic acid JM to write trust guidance in conjunction with DME pharmacy team- Guidance going through multiple governance committees, will be presented to D&T when ready. JM updated due date</p> <p>NICE Guidance JM to meet with neurology about TA758- Neurology unable to attend meeting, JM to rearrange and discuss.</p> <p>New Product Requests JM to request feedback from Dr Jose about clonidine patches in 6 months</p> <p>Clinical guidelines – Biologics and small molecules for IBD JM to meet with SS (with surgical team pharmacists) to work on updated guidance and discuss audit- Discussed to keep as a standing point for updates JG to ensure new pharmacy service to IMIC is set up JG to chase up if service was set up New action: Add guidance to agenda when updated- JM has received draft guidance and will review if can be presented</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>	<p>JM to escalate to PE&CE</p> <p>Wait until guidance is ready to be presented</p> <p>JM to meet with neurology</p> <p>Feedback due in September</p> <p>Regular updates</p> <p>JG to chase up</p> <p>JM to review draft guidance</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JG</p> <p>JM</p>	<p>3/22</p> <p>9/22</p> <p>3/22</p> <p>9/22</p> <p>5/22</p> <p>6/22</p> <p>9/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>NICE Guidance JM to check with Dr Gordins regarding TA769- JM has not received correspondence back from Dr Gordins will chase</p> <p>New Product Requests JM to write to applicants</p> <p>New Product Requests LS to update formulary</p> <p>NICE Guidance LS to update back of formulary with TAs</p> <p>MHRA Drug Safety Update April 2022 –Contact Mr Sedman about inclusion of pregabalin article in consultants newsletter. No inclusion of update in newsletter, JM to chase</p> <p>Any other business Check dermatology still require potassium permanganate- JM had no correspondence with dermatology. Simon Gaines(SG) also contacted dermatology JM to check with SG</p>	<p>Ongoing</p> <p>Complete</p> <p>Complete</p> <p>Complete</p> <p>Ongoing</p> <p>Ongoing</p>	<p>JM to remind Dr Gordins</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>JM to contact Mr Sedman</p> <p>JM to check with SG/Dermatology</p>	<p>JM</p> <p>JM</p> <p>LS</p> <p>LS</p> <p>JM</p> <p>JM</p>	<p>5/22</p> <p>7/22</p> <p>7/22</p> <p>7/22</p> <p>7/22</p> <p>7/22</p>	
2022.08.05	New Product Requests	<p>New Product Requests:</p> <p>a) Romosozumab (TA791)</p> <p>b) Faricimab (TA799 and TA800)</p> <p>c) Diroximel fumarate (TA794)</p> <p>ARIA Forms:</p> <p>d) Dostarlimab (TA779)</p> <p>e) Atezolizumab- 4 weekly</p>	<p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p>	<p>AM to write to applicants</p> <p>LS to update formulary</p>	<p>AM/L</p> <p>S</p>		
2022.08.06	IV iron Usage and formulary options	<p>JG discussed the standardising of iron preparations. If we would prefer to use a single iron preparation or if there is a clinical reason for using multiple preparations.</p> <p>AM suggested that we have 2 products as a precaution if patients have a reaction to one product we have an alternative.</p> <p>Paul O'Brien discussed that fact that diafer and venofer are for renal only while inpatient should be</p>	<p>Complete</p>	<p>To update formulary – Monofer first line IV iron, Cosmofer 2nd line and diafer and venofer for renal use only</p>	<p>JM</p>	<p>9/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		monofer and cosmofer. Suggested that cosmofer be removed from standard use and use monofer as first line iron preparation across all areas. Agreed that Monofer should be used and Cosmofer be used second line, JM to check with H50 on their usage.					
2022.08.07	NICE guidance	<p>Nice Guidance June 2022</p> <ul style="list-style-type: none"> • TA792 Filgotinib for treating moderately to severely active ulcerative colitis • TA795 Ibrutinib for treating Waldenstrom's macroglobulinaemia • TA794 Diroximel fumarate for treating relapsing–remitting multiple sclerosis • TA793 Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) • NG219 Gout: diagnosis and management • NG25 Preterm labour and birth • TA797 Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) • TA796 Venetoclax for treating chronic lymphocytic leukaemia • NG221 Reducing sexually transmitted infections • NG191 COVID-19 rapid guideline: managing COVID-19 • TA798 Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation • NG220 Multiple sclerosis in adults: management • NG200 COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) • TA802 Cemiplimab for treating advanced cutaneous squamous cell carcinoma 	<p>On formulary JM to email Prof Sebastian</p> <p>Not recommended</p> <p>On agenda</p> <p>Terminated appraisal</p> <p>Noted Update- No change required Terminated appraisal</p> <p>Update- on formulary</p> <p>Nil for D&T</p> <p>Noted</p> <p>Aria form required</p> <p>Noted- Nil for D&T</p> <p>Noted</p> <p>Aria form required</p>	JM to e-mail	JM	9/22	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> TA801 Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer TA800 Faricimab for treating wet age-related macular degeneration TA799 Faricimab for treating diabetic macular oedema NG28 Type 2 diabetes in adults: management NG18 Diabetes (type 1 and type 2) in children and young people: diagnosis and management NG222 Depression in adults: treatment and management NG17 Type 1 diabetes in adults: diagnosis and management TA804 Teduglutide for treating short bowel syndrome Team aware and will do NPR <p>July 2022</p> <ul style="list-style-type: none"> NG223 Social, emotional and mental wellbeing in primary and secondary education HST21 Setmelanotide for treating obesity caused by LEPR or POMC deficiency CG191 Pneumonia in adults: diagnosis and management TA808 Fenfluramine for treating seizures associated with Dravet syndrome Previous chairs approval JM to contact Dr Jose and Dr Ming TA807 Roxadustat for treating symptomatic anaemia in chronic kidney disease TA806 Belimumab for treating lupus nephritis (terminated appraisal) TA805 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides 	<p>Aria form required</p> <p>On agenda</p> <p>On agenda</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>New product – NPR needed</p> <p>Noted Nil for D&T Noted</p> <p>Update</p> <p>JM to contact</p> <p>JM to contact Prof Bhandari</p> <p>Terminated appraisal</p> <p>Noted</p>	<p>None</p> <p>JM to contact SJ/AM</p> <p>JM to contact SB</p>	<p>JM</p> <p>JM</p>	<p>9/22</p> <p>9/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>Dr Narayanan aware and already preparing NPR – no action needed</p> <ul style="list-style-type: none"> TA803 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs On formulary – JM to contact Dr Zaman to confirm required, send dermatology PA pathway to OO and Emily Hardaker to update dermatology PA pathway. NG191 COVID-19 rapid guideline: managing COVID-19 NG187 COVID-19 rapid guideline: vitamin D NG164 COVID-19 rapid guideline: haematopoietic stem cell transplantation TA810 Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence TA809 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease TA811 Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) NG224 Urinary tract infection in under 16s: diagnosis and management NG14 Melanoma: assessment and management 	<p>Contact RZ/EH Send pathway to OO</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Aria form required</p> <p>Check TA if HUTH required</p> <p>Terminated appraisal</p> <p>Nil for D&T</p> <p>Noted</p>	<p>JM to contact JM to send pathway</p> <p>JM to look at commissioning</p>	<p>JM JM</p> <p>JM</p>	<p>9/22 9/22</p> <p>9/22</p>	
2022.08.08	MHRA Drug safety update	<ul style="list-style-type: none"> June 2022 July 2022 	Noted				
2022.08.09	Minutes of the Safe Medication Practice Committee	Nil this month	Complete	No action required			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.08.10	Minutes from the Hull and East Riding Prescribing Committee	<ul style="list-style-type: none"> April 2022 June 2022 	Complete	No action required			
2022.08.11	Regional Medicines Optimisation Committee	<ul style="list-style-type: none"> Shared Care Protocols (SCPs) 	Noted	No action required			
2022.08.12	Clinical guidelines	<ul style="list-style-type: none"> Acute Management of Parkinson's disease including Medications via Alternative Routes of Administration- Updated guideline 	Noted	Upload to pattie			
2022.08.13	Correspondence received	<ul style="list-style-type: none"> Nil this month 					
2022.08.14	Chairs Approvals	<ul style="list-style-type: none"> Nab-paclitaxel- Dr G Bozas- Ovarian cancer Formaldehyde in a bladder instillation- Mr Krauss 	Approved Approved	No action required			
2022.08.15	Issues to escalate to PS&CE	<ul style="list-style-type: none"> Hydroxychloroquine in RA 	As per action tracker	JM to escalate			
2022.08.16	Any Other Business	<ul style="list-style-type: none"> Alteplase shortage- JM informed that there is a national shortage and has already purchased alternate stock to ensure continuation of service. Add streptokinase to formulary. IV Aspirin- JM informed that supply issue with IV aspirin and trying to source an alternative 	Add streptokinase to formulary	JM to add to formulary	JM	9/22	
2022.08.17	Date and Time of Next Meeting	8 th September 2022 8:15 am					